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OBJECTIVES: The study objective was to assess costs and the
cost effectiveness of early and late epoetin administration in
chronic renal insufﬁciency during the predialysis period in
Poland. METHODS: The analysis was based on clinical data
from systematic literature review. Only direct medical costs were
included into the study. The effectiveness was expressed as death
or dialysis avoided. The cost-effectiveness analysis from the
payer perspective was conducted. RESULTS: The mean individ-
ual treatment cost of early and late epoetin administration in
chronic renal insufﬁciency during the predialysis period was esti-
mated for €3597 (1 € = 4.035 PLN) and €2163, respectively. The
cost of death or dialysis avoided in the early and late introduced
epoetin treatment amounted to €5058 and €4429, respectively.
However 14% increment of this equation in patients early
treated with epoetin resulted in over 50% decrement of end point
appearance (initiation of dialysis or death). CONCLUSIONS:
For the majority of patients early treatment with epoetin trans-
lates into signiﬁcant delay of renal replacement therapy. Early
introduction of epoetin treatment in chronic renal insufﬁciency
patients before dialysis is cost-effective.
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Anaemia is a common complication of renal failure. Anaemia
can be treated with erythropoietin (EPO) administration, RBC
transfusion, or a combination of both. EPO has been registered
for treatment of renal anaemia in Sweden since the beginning of
the 1990s, and is the primary treatment regimen for anaemia
related to renal failure. OBJECTIVE: The objective of this study
was to carry out a cost-effectiveness analysis of treatment with
epoietin alpha compared to treatment with RBC transfusion for
patients with anaemia associated with renal failure in Sweden.
METHOD: Incremental costs associated with EPO treatment
compared with the traditional treatment therapy of blood trans-
fusion (costs of EPO, iron supplementation, administration and
surveillance, EPO complications and costs of blood transfusion)
are estimated. Swedish treatment guidelines, patient characteris-
tics and unit costs (provider perspective) are used throughout the
study. Information about QALY gains is collected from the lit-
erature. RESULTS: The estimated cost per QALY gained from
administration of EPO to renal patients in Sweden was found to
be SEK 403,921 (EUR 43,201) on average. The cost of treatment
with EPO differs widely between haemodialysis (HD) and peri-
tonealdialysis (PD) patients due to different dosages of EPO and
iron supplementation. The results were found to be sensitive
regarding assumptions on QALY gains but not regarding the cost
of blood transfusion. CONCLUSION: The estimated cost per
QALY falls within the range acceptable of the value of a QALY
in Sweden for both HD and PD patients. EPO administration to
renal patients is much more costly in Sweden than in the UK,
primarily due to higher dosage of EPO and iron supplementa-
tion in Sweden. Swedish patients, on the other hand reach higher
Hb-levels than patients in the UK.
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Benign prostatic hyperplasia (BPH) is common in older men
affecting 40% of men in their ﬁfties. If the enlarged gland begins
to press upon the urethra and to interfere with urination, then
treatment may be needed. Transurethral resection of the prostate
(TURP) is a minimally invasive treatment that has became the
gold standard for patients who are unwilling to remain on med-
ication or in whom medical therapy failed. Recently a minimally
invasive surgery treatment has shown similar results compared
to TURP, transurethral needle ablation of the prostate (PROS-
TIVA®). OBJECTIVES: To carry out an economic evaluation of
PROSTIVA® vs. TURP in non-drug respondent BHP patients in
the Spanish setting. METHODS: A Markov model was devel-
oped in order to simulate the clinical and economical conse-
quences of using PROSTIVA® or TURP in BHP. Four health
states were considered: Intervention, therapeutic success, non-
therapeutic success and permanent adverse events through a
cost-effectiveness analysis. Clinical and economical data were
retrieved from published clinical trials and validated by a clini-
cian experienced in the BHP management. Perspective of the
analysis was the National Health System perspective, so only
direct costs were included. The time horizon was 15 years with
6 months cycles, so clinical and economical results were dis-
counted at a 3% per year. A probabilistic sensitivity analysis
(PSA) was performed in order to check the variability in the
model results. All uncertain variables included were included in
PSA. RESULTS: Mean cost per patient with PROSTIVA® was
€1207 (p = 0.00) less than patients treated with TURP, but with
a decrement 0.42 QALYs (p = 0.00), which leads us to an ICER
of €2860/QALYs. Sensitivity analyses have shown consistent
results across changes in all variables. CONCLUSION: PROS-
TIVA® compared to TURP has shown to be an efﬁcient therapy
for non-drug respondents BHP patients in Spain, with an ICER
below accepted thresholds.
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BPH and associated lower urinary tract symptoms affect quality
of life of older men and could require surgery. The MTOPS study
demonstrated that the risk of overall clinical progression (includ-
ing worsening of symptoms, acute urinary retention, urinary
incontinence, renal insufﬁciency, or recurrent urinary infection)
was signiﬁcantly reduced by ﬁnasteride (−34%, p = 0.002), dox-
azosin (−39%, p < 0.001) and by the combination of both 
(−66%, p < 0.001), as compared with placebo. The clinical
beneﬁt of the combination was signiﬁcantly higher than the one
of each individual component. MTOPS study showed also that
only ﬁnasteride, alone or in combination with doxazosin reduced
signiﬁcantly (p < 0.001) the risk of invasive therapy by respec-
tively 64% and 67% compared with placebo. OBJECTIVE: To
estimate the cost-efﬁcacy of ﬁnasteride, doxazosin, and the com-
bination of both in the treatment of BPH in the perspective of
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the French Sickness Fund. METHODS: Medical consumption
was based on clinical trial data. Cost data (medical fees, hospi-
talization, surgery) were extracted from the National Health
Insurance website (www.ameli.fr) and from PMSI database.
Cost-efﬁcacy ratios were calculated to compare therapies when
signiﬁcant differences were demonstrated on study outcomes.
RESULTS: Costs per clinical progression prevented were respec-
tively €7404 for ﬁnasteride, €7314 for doxazosin, and €8206 
for the combination of both as compared with placebo. Cost-
efﬁcacy ratio (additional drug costs per invasive therapy avoided)
was €16,153 for ﬁnasteride versus placebo, and €3153 versus
doxazosin. It was €16,400 for combination therapy versus dox-
azosin, and €28,779 versus placebo. CONCLUSION: Cost-
efﬁcacy ratios of ﬁnasteride and doxazosin for the prevention of
clinical progression were in the same range. The cost-efﬁcacy
ratio of the combination was slightly higher, but with a further
signiﬁcant clinical beneﬁt. Only ﬁnasteride alone or in combina-
tion with doxazosine reduced the risk of invasive therapy. Its
cost-efﬁcacy ratio for preventing invasive therapy remains in an
acceptable range in the French setting.
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OBJECTIVES: To estimate the direct annual costs (from May
2004 to May 2005) associated with Lower Urinary Tract Symp-
toms (LUTS) in Italian women from the NHS perspective. To
assess, at the same time, costs borne by subgroup of women with
Urinary Incontinence (UI). METHODS: This evaluation was
carried out as a part of the FLOW project: a 2-year observational
study aimed at evaluating the prevalence, incidence and remis-
sion rates of LUTS in a large sample of women followed at 39
Italian Urology Clinics. NHS costs, such as specialist visits, hos-
pitalizations, therapy and laboratory tests were collected retro-
spectively. The Dowell-Bryant Incontinence Cost Index (DBICI)
was used to investigate personal UI costs, such as: disposable
pads, re-usable incontinence products, laundry and health pro-
fessional expenditure, surgery/diagnostic investigation and med-
ication. RESULTS: A sample of 279 women were re-evaluated
after two years follow-up. The estimated total annual cost to the
Italian NHS for curing female with LUTS ranged between
€70,488,843 and €1,325,850,296. The average annual NHS
costs per patient in our sample were €232.90, of which the major
components were: rehabilitative therapy (€83.24), surgical
therapy (€64.54) and instrumental tests (€47.39). As for women
with UI, surgery interventions accounted for 35% of the total
NHS costs Vs 27% for whole study sample with LUTS. Regard-
ing women with UI, the average annual personal cost estimated
by DBICI was 215.21€ of which disposable pads and medica-
tions accounted respectively for 50% and 33%. CONCLUSION:
After 2-yr follow-up the higher costs for the NHS seem to be
associated to rehabilitative therapy and surgical procedures.
Some differences were detected among the NHS resources used
by the subgroup of women with UI. Costs borne by women with
UI were quite high and the most important estimated component
were the use of disposable products.
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OBJECTIVES: This study’s objective was to estimate the burden
of illness (BOI) of overactive bladder (OAB) and urinary urge
incontinence (UUI) in the over 40 population using recent ﬁnd-
ings from a prevalence survey (EPIC) and recent published liter-
ature. METHODS: New prevalence data was incorporated into
a previously published BOI model. A literature search obtained
data pertaining to consequence probabilities for OAB, UUI and
related co-morbidities. The model was then used to produce esti-
mates of the total burden of OAB in 6 countries. RESULTS: It
is estimated, for these 6 countries, that that over 20 million
people have OAB symptoms of which 2 million have UUI. 
The annual total direct cost of OAB was calculated to be 12
billion euros (2005 prices). 80% of this cost is associated with
UUI. The total costs per country are: €257,402,489 Canada,
€5,301,967,560 Germany, €4,536,571,901 Italy, €550,697,531
Spain, €327,640,146 Sweden and €1,026,091,457 UK. The cost
of OAB management (medical visits, diagnostic testing, inconti-
nence pads and drugs) and co-morbidities (UTIs, skin conditions,
falls/fractures, depression and increased likelihood of nursing
home admission) ranged from €2600 in Spain to €35,000 in Italy
per person. The largest cost driver was the increased likelihood
of nursing home admission followed by the cost of incontinence
pads. CONCLUSIONS: These estimates of the total direct cost
burden of OAB are higher than previous published estimates.
This is due to current prevalence rates and probabilities of devel-
oping consequences of uncontrolled OAB. The OAB symptom
UUI is associated with the most co-morbidity costs. These 
COI results may under-estimate the true costs, as OAB also
affects people under 40 years old. Indirect and intangible costs
have also been excluded. Cost-effective treatments for OAB and
UUI in particular have the potential to signiﬁcantly improve the
allocation of health care resources in a growing proportion of
the population.
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OBJECTIVES: End-stage renal failure patients are normally
anaemic due to failure of renal to produce endogenous erythro-
poietin (EPO). Erythropoietin is used to treat anaemia in these
patients but the drug is expensive. The objectives of this study
were to determine the life expectancy, the improvement in quality
of life associated with haemoglobin, the utility of the dialysis
patients, and the cost utility as cost per quality-adjusted life year
(QALY) saved. METHODS: The perspective was for the health
provider and the treatments compared were haemodialysis and
CAPD. The National Renal Registry database for the period of
1997–2004 formed the basis of patient selection. There were 406
haemodialysis and 333 continuous ambulatory peritoneal dialy-
sis (CAPD) patients to evaluate the utility of quality of life. The
health-related quality of life questionnaires and the time trade-
off were used to acquire the quality of life index and the utility.
